# Moleculin Biotech Inc. (MBRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $3M  
**Price:** $2.70 (+8.00%)

> Moleculin Biotech Inc. is a clinical-stage pharmaceutical company that primarily focuses on the development of oncology drug candidates. Based in Houston, Texas, the company concentrates its efforts on addressing unmet medical needs related to cancer. Moleculin Biotech is notable for its diverse pipeline of drug candidates, which includes small molecules targeting key biological pathways involved in cancer cell proliferation and survival. The company leverages its novel technologies, such as its Immune/Transcription Modulary Technology, to develop potential treatments that can be more effective and less toxic than existing therapies. Moleculin Biotech's research and developments are particularly influential within the biotechnology and pharmaceutical sectors, contributing to advancements in cancer treatment and offering hope for new therapeutic options. Through its innovative approach to drug development, Moleculin Biotech Inc. plays a significant role in the broader scientific and medical community, aiming to translate groundbreaking research into practical treatments that can improve patient outcomes.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | — | — | -$25M | -$34M | $-28.42 |
| 2024 | — | — | -$27M | -$22M | $-158.00 |
| 2023 | — | — | -$30M | -$30M | $-15.15 |
| 2022 | — | — | -$31M | -$29M | $-15.15 |
| 2021 | — | — | -$23M | -$16M | $-8.85 |
| 2020 | — | — | -$20M | -$17M | $-26.40 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $22M | $7M | $15M | $9M | $222,000 |
| 2024 | $17M | $11M | $6M | $4M | $358,000 |
| 2023 | $38M | $12M | $26M | $24M | $474,000 |
| 2022 | $57M | $5M | $52M | $43M | $335,000 |
| 2021 | $84M | $5M | $79M | $71M | $63,000 |
| 2020 | $29M | $11M | $18M | $15M | $159,000 |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$31M | — | -$23M |
| 2024 | -$20M | -$13,000 | -$24M |
| 2023 | -$26M | -$124,000 | -$24M |
| 2022 | -$26M | -$67,000 | -$28M |
| 2021 | -$13M | -$19,000 | -$19M |
| 2020 | -$16M | -$374,000 | -$18M |

Source: [CompaniesByCap](https://companiesbycap.com/company/MBRX)